Tirzepatide Mechanism of Action: Dual GIP/GLP-1 Receptor Agonism and the Beta-Cell Record

The short version

Tirzepatide's mechanism of action is dual incretin agonism — it activates both the GIP receptor and the GLP-1 receptor with a single molecule.

GIP and GLP-1 are hormones released from the gut after eating. When blood sugar rises, they tell the pancreas to release insulin. When blood sugar is low, they go quiet. That glucose-dependency is what makes this class of drug relatively safe compared with older diabetes medicines that push insulin secretion regardless of blood sugar levels.

Tirzepatide's key biological property is that it engages both receptors at once. Lab tests showed it hits the GIP receptor more strongly than the GLP-1 receptor, making it an "imbalanced" dual agonist — and at the GLP-1 receptor it behaves differently than native GLP-1, preferring one cellular signal (cAMP) over another (beta-arrestin). Both properties may help explain why it outperforms single-receptor drugs in trials ^[2].

In a 117-person clinical study measuring how the pancreas secretes insulin and how well the body uses it (called a glucose clamp), tirzepatide improved the combined insulin secretion-plus-sensitivity score (the disposition index) significantly more than a leading comparison drug ^[8]. That is the mechanistic signature this site centres on.

Tirzepatide mechanism of action: the receptor pharmacology

The tirzepatide mechanism of action was characterised in detail in 2020 by Willard et al. in JCI Insight. In receptor occupancy and downstream signalling assays using recombinant human GIP and GLP-1 receptors and primary islet preparations, the study established three findings ^[2]:

1. Imbalanced dual agonism. Tirzepatide engaged the GIP receptor to a greater degree than the GLP-1 receptor, making it a GIPR-preferring dual agonist rather than an equal-intensity dual agonist.
2. Biased GLP-1 receptor signalling. At the GLP-1 receptor, tirzepatide showed biased agonism — it favoured cAMP (cyclic adenosine monophosphate — the intracellular messenger that drives insulin secretion) generation over beta-arrestin recruitment. Beta-arrestin typically promotes receptor internalisation and degradation; reduced beta-arrestin engagement leaves more GLP-1 receptors at the cell surface, potentially sustaining the insulin-secretion signal longer.
3. Beta-arrestin1 limits the GLP-1 insulin response but not the GIP or tirzepatide response. In primary islet experiments, blocking beta-arrestin1 increased the insulin response to GLP-1 but had no effect with GIP or tirzepatide — suggesting tirzepatide already bypasses this limiting pathway.

The original discovery paper (Coskun et al., Mol Metab, 2018) established that dual GIP/GLP-1 agonism produced greater body weight and food intake reductions in mice than a selective GLP-1 receptor agonist given at matched exposures, and that the Phase 1 programme in 142 human subjects supported once-weekly dosing and showed reductions in fasting glucose and body weight versus placebo ^[1].

The combined picture from the pharmacology literature: tirzepatide hits both incretin receptors with an imbalance favouring the GIP receptor and engages the GLP-1 receptor in a way that favours the insulin-secretion pathway over the receptor-internalisation pathway. Both features are proposed to amplify the glucose-lowering and weight-reducing effects relative to selective GLP-1 agonism.

Beta-cell function and insulin sensitivity: the disposition-index evidence

The clearest mechanistic evidence for tirzepatide's superiority over selective GLP-1 receptor agonism comes from the Heise et al. multicentre phase 1 RCT (Lancet Diabetes Endocrinol, 2022, NCT03951753, n=117) ^[8]. The trial randomised adults with type 2 diabetes to tirzepatide 15 mg, semaglutide 1 mg, or placebo over 28 weeks, then performed hyperinsulinaemic-euglycaemic clamp studies with meal testing.

The primary endpoint was the clamp disposition index — a composite of the insulin secretion rate and the insulin sensitivity (M-value, expressed as mg/min/kg of glucose infused). The disposition index integrates how much insulin the pancreatic beta cells secrete with how effectively that insulin lowers blood glucose — it is the key metric of overall glucose-regulatory capacity.

Results:

• Clamp disposition index ETD vs placebo: 1.92 (95% CI 1.59–2.24; p<0.0001) ^[8]
• Clamp disposition index ETD vs semaglutide: 0.84 (95% CI 0.46–1.21; p<0.0001) ^[8]
• Insulin secretion rate ETD vs semaglutide: 102.09 pmol/min/m² ^[8]
• M-value (insulin sensitivity) ETD vs semaglutide: 1.52 mg/min/kg ^[8]
• Tirzepatide also reduced meal-test insulin and glucagon excursions more than semaglutide ^[8]

A follow-up mechanistic substudy (Heise et al., J Clin Endocrinol Metab, 2024) confirmed improved islet-cell function and insulin sensitivity markers across the SURPASS dose range ^[9]. In the SURPASS-1 monotherapy setting, Thomas et al. (J Endocr Soc, 2023) reported similar improvements in beta-cell function and insulin sensitivity under monotherapy at all three doses ^[10].

A SURPASS J-mono analysis (Hamamoto et al., Diabetes Ther, 2025, n=636 Japanese patients with T2D) found all three tirzepatide doses significantly improved HOMA2-%S (surrogate marker of insulin sensitivity) and HOMA2-%B (surrogate marker of beta-cell function) versus dulaglutide at week 52, with significant reductions in fasting insulin and C-peptide ^[19].

A SURMOUNT-1 post-hoc analysis (Mari et al., Diabetes Care, 2025) in 2,539 adults with obesity or overweight and prediabetes or normoglycaemia found that weight reduction and tirzepatide treatment both improved insulin sensitivity and beta-cell function, with beta-cell function enhancement being partly weight-independent — suggesting a direct drug effect on pancreatic function ^[20].

This body of evidence constitutes the beta-cell/insulin-sensitivity argument for tirzepatide's dual mechanism: that adding GIP receptor agonism to GLP-1 receptor agonism produces a measurably greater improvement in the functional capacity of the glucose-regulatory system than GLP-1 agonism alone.

Glucagon suppression, gastric emptying, and appetite regulation

Beyond insulin secretion and insulin sensitivity, the tirzepatide mechanism of action engages three additional physiological pathways documented in the trial literature:

Glucagon suppression. Glucagon (the pancreatic hormone that raises blood glucose — incretin agonists suppress its glucose-dependent secretion) excursions on meal testing were reduced more with tirzepatide than semaglutide in the Heise 2022 clamp study ^[8]. Suppressing inappropriate glucagon secretion reduces the liver's glucose output and contributes to the HbA1c reduction.

Delayed gastric emptying. Tirzepatide transiently delays gastric emptying — the rate at which the stomach passes its contents into the small intestine — to a degree comparable to selective long-acting GLP-1 receptor agonists, according to Urva et al. (Diabetes Obes Metab, 2020) ^[21]. The delay attenuates with continued treatment. Slower gastric emptying blunts the post-meal glucose spike and contributes to satiety.

Appetite and food intake. In the original mouse studies, tirzepatide reduced food intake more than a selective GLP-1 receptor agonist at matched exposures ^[1]. In clinical trials, decreased appetite was among the most commonly reported patient experiences. The brain regions that express both GIP and GLP-1 receptors — particularly in the hypothalamus and brainstem — are an active area of research into the appetite-regulation mechanism.

The convergence of these four pathways (increased insulin secretion, improved insulin sensitivity, glucagon suppression, and appetite regulation) is what the SURPASS and SURMOUNT trial data reflect.